1. Validation of a novel direct method to determine reduced adherence to atorvastatin therapy, European Heart Journal Cardiovascular Pharmacotherapy 2024
  2. The atorvastatin metabolite pattern in muscle tissue and blood plasma is associated with statin muscle side effects in patients with coronary heart disease; An exploratory case-control study, Atherosclerosis Plus 2024
  3. A multi-component intervention increased access to smoking cessation treatment after hospitalization for atherosclerotic cardiovascular disease. A randomized trial.European Heart Journal Open, 2024
  4. Treatment patterns and adherence to lipid-lowering drugs during eight-year follow-up after a coronary heart disease event. Atherosclerosis, 2024
  5. Statin adherence in coronary outpatients: the relationship between a novel direct method and pharmacy registry data. Poster presentasjon av Jonas Pivoriunas mfl. (NORCOR gruppen). ESC Preventive Cardiology Annual Congress, 25 April –  27 April 2024 Aten – Hellas.
  6. Adipose tissue insulin resistance in South Asian and Nordic women after gestational diabetes mellitus. Metabolites 2024
  7. 2023 ESC guidelines for the mamagement of cardiovascular disease in patients with diabetes. Hjerteforum 2024 (s. 29)
  8. Statin adherence in coronary outpatients: a novel direct method compared with pharmacy registry data. European Journal of Preventive Cardiology 2024
  9. Cognitive behavioural therapy for insomnia (CBT-I) in patients with coronary heart disease: a protocol for a randomized controlled trial with six months follow-up. European Journal of Preventive Cardiology 2024
  10. The effect of atorvastatin on mevalonate levels in blood plasma in patients with coronary heart disease and muscle side effects. European Journal of Preventive Cardiology 2024